These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12796326)

  • 1. Should cost-effectiveness take the blame?
    McGregor M
    CMAJ; 2003 Jun; 168(12):1528; author reply 1528-9. PubMed ID: 12796326
    [No Abstract]   [Full Text] [Related]  

  • 2. Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?
    Gafni A; Birch S
    CMAJ; 2003 Apr; 168(7):849-51. PubMed ID: 12668543
    [No Abstract]   [Full Text] [Related]  

  • 3. I why we need a PDL and how it works.
    Hauser H
    Tex Med; 2004 Apr; 100(4):7. PubMed ID: 15303483
    [No Abstract]   [Full Text] [Related]  

  • 4. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
    Laupacis A
    CMAJ; 2002 Jan; 166(1):44-7. PubMed ID: 11800247
    [No Abstract]   [Full Text] [Related]  

  • 5. How expert opinion influences P&T decisions.
    Manag Care; 2010 May; 19(5):52. PubMed ID: 20524369
    [No Abstract]   [Full Text] [Related]  

  • 6. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 10. Engineering new strategies in specialty pharmacy management.
    Edlin M
    AHIP Cover; 2004; 45(5):34-9. PubMed ID: 15499743
    [No Abstract]   [Full Text] [Related]  

  • 11. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 13. Reflections on a month in the life of the Ontario Drug Benefit Plan.
    McIsaac W; Naylor CD; Anderson GM; O'Brien BJ
    CMAJ; 1994 Feb; 150(4):473-7. PubMed ID: 8313259
    [No Abstract]   [Full Text] [Related]  

  • 14. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACAPN News.
    Stephan LS
    J Child Adolesc Psychiatr Nurs; 2009 May; 22(2):108. PubMed ID: 19490282
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Part D: practical and policy implications for family physicians.
    Mallya G; Bazemore A
    Am Fam Physician; 2006 Feb; 73(3):395-6. PubMed ID: 16477884
    [No Abstract]   [Full Text] [Related]  

  • 19. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

  • 20. The focus on true value in the health care system.
    Giaquinta D
    Manag Care Interface; 2007 Apr; 20(4):40-1. PubMed ID: 17474329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.